Private Foundation

EMERALD FOUNDATION INC CO SOLOMON BLUM HEYMANN

EMERALD FOUNDATION INC CO SOLOMON BLUM HEYMANN is a Private Foundation headquartered in NEW YORK, NY. Financial data from the 2024 filing: $1.4M revenue, $2.5M expenses, $25.3M total assets. IRS filings disclose 135 grants awarded by this foundation, totaling roughly $11.1M.

EIN: 133912580 NEW YORK, NY Latest filing: 2024

Total Revenue$1.4M

Total Expenses$2.5M

Total Assets$25.3M

Grants Given135

Grant Total$11.1M

Filing Years2020–2024

Sample Grants Given

MASSACHUSETTS INSTITUTE OF TECHNOLO

Cambridge, MA · 2024

To study how ferroptosis-based strategies can enhance the efficacy of immunotherapies in breast cancer.

$87,500

UNIVERSITY OF MARYLAND SCH OF MEDIC

BALTIMORE, MD · 2024

TO INVESTIGATE THE REGULATION OF TREG LYMPHATIC TUMOR MIGRATION AND THE INTERACTION AMONG TREGS, LYMPHATIC ENDOTHELIAL CELLS, AND TUMORS TO DEVELOP STRATEGIES OF DELIVERING TARGETED THERAPIES LOCALLY INSTEAD OF SYSTEMICALLY.

$75,000

UNIVERSITY OF MARYLAND SCH OF MEDIC

BALTIMORE, MD · 2024

To investigate the regulation of Treg lymphatic tumor migration and the interaction among Tregs, lymphatic endothelial cells, and tumors to develop strategies of delivering targeted therapies locally instead of systemically.

$75,000

MASSACHUSETTS INSTITUTE OF TECHNOLO

CAMBRIDGE, MA · 2024

To enhance nanoparticle accumulation in desired cell types to develop more effective and safer targeted nanotherapies.

$75,000

NYU SCHOOL OF MEDICINE

New York, NY · 2024

To examine the cellular mechanisms through which dendrite-centric Alzheimer's disease pathologies result in cognitive dysfunction and hyper-excitability.

$75,000

Showing up to 5 of 135 total records — full history available with membership.

Officers & Directors

Pres/director Andrew W Heymann

Director Erika Kellerhals

Vice President James P Mahaffey

Director Luca Cantelli

Treasurer William Blum

Officer compensation and complete director data available with membership.

Top Grant Purposes

To investigate the role of tRNA-derived fragments and the genes they regulate in breast cancer progression and metastasis.

$475,000 4 grants

To investigate the role of diet and nutrient availability in tumor growth, progression, and response to treatment.

$450,000 3 grants

To investigate how the transfer of alpha-synuclein between cells in the nervous system induces neuroinflammation that drives Parkinson's Disease pathogenesis.

$450,000 3 grants

To analyze the potential therapeutic effect of blocking fatty acid synthesis in non-small cell lung cancer through the use of novel enzymatic inhibitors.

$450,000 3 grants

To uncover and validate druggable targets that can be combined with MEK/ERK inhibitors to treat RAS pathway-driven malignancies, especially melanoma.

$450,000 3 grants

Financial Trends

Year	Revenue	Expenses	Assets
2024	$1.4M	$2.5M	$25.3M
2023	$1.0M	$2.2M	$26.4M
2022	$1.3M	$2.1M	$27.7M
2021	$1.8M	$2.2M	$28.5M
2020	$814K	$1.9M	$29.0M

Between 2020 and 2024, reported annual revenue grew from $814K to $1.4M (+71%), with total assets most recently reported at $25.3M.

Interactive year-over-year charts and full filing details available with membership.

Grant Geography

Grants from this foundation were reported to recipients in CA, DC, FL, IL, KY, MA, and 4 other states.

CADCFLILKYMAMDMIMNNJ

Full geographic grant map with state-by-state breakdown available with membership.

See the full picture for EMERALD FOUNDATION INC CO SOLOMON BLUM HEYMANN

Complete financials, all 135 grant records, officer compensation, year-over-year trend charts, a geographic grant map, and data exports — across 498,000+ organizations.

Full Financial History Complete Grant Activity Officer Compensation Year-over-Year Charts Geographic Grant Map Data Exports